Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
Status:
Active, not recruiting
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well sorafenib tosylate and chemotherapy work in treating
older patients with acute myeloid leukemia (AML). Sorafenib tosylate may stop the growth of
cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in
chemotherapy, such as daunorubicin hydrochloride and cytarabine, work in different ways to
stop the growth of cancer cells, either by killing the cells or by stopping them from
dividing. Giving sorafenib tosylate and combination chemotherapy may be an effective
treatment for AML.